24 December 2012

AquaBounty Technologies
("AquaBounty" or "the Company")

Update on FDA Approval
Environmental Assessment to be published for public comment

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces that it has been notified by the U.S. Food and Drug Administration ("FDA") that the Environmental Assessment ("EA") on its New Animal Drug Application ("NADA") for AquAdvantage Salmon® ("AAS") will be published in the Federal Register on 26 December 2012. A notice appeared in the Federal Register to that effect.

The EA will be subject to a 60 day period for public comment. The FDA is also making available for comment its preliminary Finding of No Significant Impact (FONSI).

As previously reported, the FDA held a public meeting of its Veterinary Medicine Advisory Committee in September 2010 to review its findings and the conclusion of its panel of experts that AAS is indistinguishable from other Atlantic salmon, is safe to eat and does not pose a threat to the environment under its conditions of use. Subsequently, the FDA has been fulfilling its obligations under the U.S. National Environmental Policy Act, which requires that all federal agencies consider the possible environmental impacts of any action which they authorize.

The FDA has not provided the Company with an indication of the process, or associated timing, that will occur after the conclusion of the period for public comment.

For further information, please contact:

AquaBounty Technologies David Frank, Chief Financial Officer	+1 978 648 6000
Nomura Code Securities Giles Balleny	+44 (0)20 7776 1200
Luther Pendragon Harry Chathli, Claire Norbury	+44 (0)20 7618 9100